Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVROBIO and Tectonic Therapeutic Announce Merger","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","amount":"$130.7 million","upfrontCash":"Undisclosed","newsHeadline":"AVROBIO and Tectonic Therapeutic Announce Merger","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Tectonic Therapeutic

    Menu

    Tectonic Therapeutic

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tectonic Therapeutic

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure

              Details:

              TX45 is an investigational long-acting relaxin-Fc fusion molecule. It is being evaluated for the treatment of group 2 pulmonary hypertension secondary to heart failure with preserved ejection fraction.

              Lead Product(s): Relaxin-2 protein, human

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TX45

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tectonic Therapeutic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AVROBIO and Tectonic Therapeutic Announce Merger

              Details:

              The combined company will focus on advancing Tectonic’s pipeline, including TX45 (TX000045), a Fc-relaxin fusion protein targeting the RXFP1 receptor and a potential best-in-class agent.

              Lead Product(s): TX000045

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TX45

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Avrobio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger January 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tectonic Therapeutic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AVROBIO and Tectonic Therapeutic Announce Merger

              Details:

              The proceeds will be used to advance Tectonic’s pipeline, including TX45 (TX000045), a Fc-relaxin fusion protein targeting the RXFP1 receptor and a potential best-in-class agent.

              Lead Product(s): TX000045

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TX45

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: TAS Partners

              Deal Size: $130.7 million Upfront Cash: Undisclosed

              Deal Type: Private Placement January 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tectonic Therapeutic

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic

              Details:

              TX45 (TX000045), a Fc-relaxin fusion protein targeting the RXFP1 receptor and a potential best-in-class agent, resulting from protein engineering efforts to overcome the human hormone’s biophysical property limitations.

              Lead Product(s): TX000045

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: TX45

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY